Monthly Archives: April 2012

The Endangered Species Act of 2012

No, we do not refer to darter fish, the Algerian Ribbed Newt, or Macgregor’s Skink. Those species are thriving compared to NIR’s roster of endangered species, which includes neuro-Sellside Analysts and neuro-IPOs. While there have been rumors of sightings in … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment

Amyvid and Irrelevance

The FDA finally gave marketing approval to Lilly’s (via Avid) Amyvid/florbetapirradio-labeled imaging agent, for use in PET-scan identification of beta-amyloid plaque. Approval had been delayed due to concerns regarding interrater variability/reliability. But reliability is not, in our view, the biggest … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , | 2 Comments

Depression Trial Contrarians

The latest issue of Neuropsychopharmacology has a provocative article by Undurraga and Balderassini regarding a meta-analysis they conducted of some thirty years of depression trials, an area that has grown increasingly and expensively frustrating as trials have been commonly compromised … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment